Compounds / DSIP

DSIP

Also known as: Delta Sleep-Inducing Peptide, Emideltide

Early clinical Not FDA-approved · PCAC review July 2026 Category: Other

The compounds described in this library are research-use-labeled chemicals and are not FDA-approved for human use. This content is factual scientific reference drawn from published literature. It is not medical, dosing, or purchasing advice. VialReport does not sell, supply, or distribute any compound.

Short summary

A nonapeptide first isolated from rabbit brain during sleep research in the 1970s. Despite the name, its role in sleep regulation has never been firmly established. Not FDA-approved.

Dive deeper

Origin and Development

Isolated by Schoenenberger and Monnier from cerebral venous blood of rabbits during induced sleep, and named for the delta-wave activity observed. The naming has proved more durable than the underlying finding.

Mechanism as Understood in the Literature

Not well established. Proposed mechanisms in the literature include interactions with opioid systems and effects on stress response, but there is no consensus mechanism, and even the endogenous role of the peptide remains debated.

Research Status

Human data exists but is old, small, and inconsistent. The badge reflects that small controlled human studies do exist, correcting an earlier "Preclinical" classification. Several controlled human studies were conducted in the 1980s and early 1990s, including double-blind and placebo-controlled insomnia work, using intravenous administration. Results were mixed and often of limited clinical significance. Those studies were underpowered, used older methods, did not lead to a modern development program, and do not support claims made for subcutaneous research-market products. This is a case where the name carries more weight than the data.

Regulatory status

Not FDA-approved for any indication. Removed from the FDA's Category 2 bulk drug substances list in April 2026 under the name Emideltide, without being moved to Category 1, and scheduled for Pharmacy Compounding Advisory Committee review on July 23, 2026.

Commonly Confused With

The name itself is the main source of confusion, since it asserts a function that the evidence does not clearly support. Also appears in regulatory documents as Emideltide, which is not obviously the same compound to a lay reader.

How This Compound Is Marketed

Vendor marketing for this compound typically references sleep, stress, and recovery. VialReport does not evaluate or endorse these claims. See Research Status above for what the published literature actually establishes.

Analytical Profile

Nine amino acids, sequence WAGGDASGE, molecular weight approximately 849 Da. Straightforward to characterize by mass against a reference standard.

Stability and Handling

Supplied lyophilized. Stable lyophilized at reduced temperature.

Key Literature

  1. 01 Schoenenberger GA, Monnier M. Characterization of a delta-electroencephalogram (-sleep)-inducing peptide. Proc Natl Acad Sci USA. 1977;74(3):1282-1286.
  2. 02 Graf MV, Kastin AJ. Delta-sleep-inducing peptide (DSIP): a review. Neurosci Biobehav Rev. 1984;8(1):83-93.

VialReport publishes factual reference information and independent test data. Nothing here is medical, dosing, or purchasing advice.

Published reports

Reports for DSIP

No reports for this compound yet.

Want a vendor’s version of this compound tested? Request it and we’ll notify you when a report publishes.

Request a test

Stay current

Get notified when new reports publish.

No membership required. We email findings when they're published. Not updates, not promotions, just reports.

Powered by MailerLite. No spam. Unsubscribe anytime.